1. Home
  2. TCPC vs MYGN Comparison

TCPC vs MYGN Comparison

Compare TCPC & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock TCP Capital Corp.

TCPC

BlackRock TCP Capital Corp.

SELL

Current Price

$4.10

Market Cap

337.3M

Sector

Finance

ML Signal

SELL

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

SELL

Current Price

$5.57

Market Cap

372.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TCPC
MYGN
Founded
2006
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
337.3M
372.1M
IPO Year
2006
1996

Fundamental Metrics

Financial Performance
Metric
TCPC
MYGN
Price
$4.10
$5.57
Analyst Decision
Hold
Hold
Analyst Count
4
9
Target Price
$4.33
★ $5.90
AVG Volume (30 Days)
805.0K
★ 3.0M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
★ 16.55%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $771,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 2.33
52 Week Low
$3.08
$2.74
52 Week High
$6.25
$8.09

Technical Indicators

Market Signals
Indicator
TCPC
MYGN
Relative Strength Index (RSI) 47.25 51.56
Support Level $4.07 $4.24
Resistance Level $4.24 $6.34
Average True Range (ATR) 0.13 0.36
MACD -0.02 -0.13
Stochastic Oscillator 9.46 6.54

Price Performance

Historical Comparison
TCPC
MYGN

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: